Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Keyphrases

• Placebo 100%
• Phase II Study 100%
• Progressive multiple Sclerosis 100%
• Siponimod 100%
• Disability Progression 25%
• Confirmed Disability Progression 25%
• Multiple Sclerosis 16%
• Placebo Groups 16%
• Between-group 8%
• Walking Aids 8%
• Initial Dose 8%
• Adverse Events 8%
• Hypertension 8%
• Hazard Ratio 8%
• Malignancy 8%
• Dose Effect 8%
• Fatality 8%
• Safety Profile 8%
• Serious Adverse Events 8%
• Liver Transaminases 8%
• Phase II Trial 8%
• Consent Forms 8%
• Treatment Initiation 8%
• Varicella Zoster 8%
• Lymphopenia 8%
• Safe Set 8%
• Sphingosine-1-phosphate 8%
• Bradycardia 8%
• Convulsion 8%
• First Dose 8%
• Once-daily 8%
• Pharma 8%
• Novartis 8%
• Interactive Response 8%
• Expanded Disability Status Scale 8%
• Relative Risk Reduction 8%
• Dose Titration 8%
• Bradyarrhythmia 8%
• Hospital Clinic 8%
• Response Technology 8%
• Macular Edema 8%
• Sphingosine-1-phosphate Modulators 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Siponimod 100%
• Multiple Sclerosis 100%
• Adverse Event 16%
• Sphingosine 1 Phosphate 16%
• Infection 8%
• Fatality 8%
• Aminotransferase 8%
• Varicella Zoster Virus 8%
• Lymphocytopenia 8%
• Expanded Disability Status Scale 8%
• Macular Edema 8%

Neuroscience

• Secondary Progressive Multiple Sclerosis 100%
• Placebo 100%
• Multiple Sclerosis 22%
• Sphingosine 1 Phosphate 22%
• Hypertension 11%
• Transaminase 11%
• Expanded Disability Status Scale 11%
• Lymphocytopenia 11%
• Varicella Zoster Virus 11%